Hindustan Agrigenetics board to meet on May 30
Hindustan Agrigenetics Limited board meets on May 30, 2026, to consider audited FY26 results. Trading window closed until 48 hours post-filing.

*this image is generated using AI for illustrative purposes only.
Hindustan Agrigenetics Limited has announced that its board of directors will meet on Saturday, May 30, 2026. The primary agenda of the meeting is to consider and approve the audited financial results of the company for the quarter and financial year ended March 31, 2026. The meeting is being convened in compliance with Regulation 29 of the SEBI (LODR) Regulations, 2015.
Board Meeting Agenda
The board will deliberate on the audited financial statements for the specified period. The approval of these results is a statutory requirement and will be followed by the necessary filings with the stock exchanges.
Trading Window Closure
In line with regulatory norms, the trading window for dealing in the securities of the company remains closed. This restriction applies to all directors, officers, designated persons, and their immediate relatives. The window will stay shut until the end of 48 hours after the audited financial results for the quarter and financial year ended March 31, 2026 are approved by the board and filed with the stock exchange.
Company Information
| Detail | Information |
|---|---|
| Company Name | Hindustan Agrigenetics Limited |
| CIN | L01119DL1990PLC040979 |
| ISIN | INE092301014 |
| Registered Office | C-1/5, Second Floor, Safdarjung Development Area, Hauz Khas, New Delhi-110016 |
The intimation was sent to BSE Limited on May 21, 2026, by Rajendra Naniwadekar, Managing Director of the company.
How have Hindustan Agrigenetics Limited's revenue and profitability trends evolved over the past few fiscal years, and what growth trajectory might the FY2026 results reveal?
What strategic initiatives or expansion plans is Hindustan Agrigenetics likely to announce alongside its FY2026 financial results that could impact its stock performance?
How might the company's financial results compare to peers in the agrigenetics and agri-biotech sector, and what does this indicate about its competitive positioning?

































